Devices and solutions for prevention of sexually transmitted diseases
Provided herein are antiviral compounds and methods of culturing microalgae to produce polysaccharides. Included in the invention are methods of producing novel polysaccharides with high antiviral avtivity. Also provided are methods of using polysaccharides for applications such as preventing or treating viral infections and providing prophylaxis and treatment for sexually transmitted diseases.
1 - 23 . (canceled)
24 . A sexually transmitted disease prevention kit or composition comprising:
a. a solution comprising a polysaccharide produced from microalgae; and
b. a prophylactic device.
25 . The kit or composition of claim 24 , wherein the device is a condom that is packaged in direct contact with the solution.
26 . The kit or composition of claim 24 , wherein the composition lacks a lubricant other than polysaccharide.
27 . The kit or composition of claim 24 , wherein the polysaccharide provides both lubricant function and antiviral activity.
28 . The kit or composition of claim 24 , wherein the polysaccharide is sulfated.
29 . The kit or composition of claim 24 , wherein the microalgae is selected from Table 1.
30 . The kit or composition of claim 25 , wherein the microalgae is selected from the group consisting of Porphyridium sp. and Porphyridium cruentum.
31 . The kit or composition of claim 24 , wherein the polysaccharide is associated with a fusion protein comprising a first protein with at least 60% amino acid identity with the protein of SEQ ID NO: 21, and a second protein.
32 . The kit or composition of claim 31 , wherein the second protein is an antibody that selectively binds to an antigen from a pathogen selected from the group consisting of HIV, Herpes Simplex Virus, gonorrhea, Chlamydia, Human Papillomavirus, and Trichomoniasis.
33 - 40 . (canceled)
41 . A method of treating or effecting prophylaxis of a mammal having or at risk of a viral infection comprising administering a polysaccharide produced by microalgae to the mammal and thereby treating or effecting prophylaxis of the mammal.
42 . The method of claim 41 , wherein the administration is mucosal.
43 . The method of claim 41 , wherein the administration is parenteral.
44 . The method of claim 43 , wherein the average molecular weight of the polysaccharide is about 100,000 daltons.
45 . The method of claim 43 , wherein the average molecular weight of the polysaccharide is about 50,000 daltons.
46 . The method of claim 41 , wherein the polysaccharide is produced by a microalgae listed in Table 1.
47 . The method of claim 46 , wherein the microalgae is of the genus Porphyridium.
48 - 63 . (canceled)
64 . A method of purifying an exopolysaccharide from cultures of cells of red microalgae comprising:
a. culturing red microalgae cells;
b. separating cells from culture media;
c. adding isopropanol to the culture media; and
d. separating precipitated exopolysaccharide from the solution.
65 - 66 . (canceled)
67 . The method of claim 64 , wherein the concentration of isopropanol used to precipitate the exopolysaccharide is between about 36% and 40% vol/vol.
68 . The method of claim 64 , wherein the concentration of isopropanol used to precipitate the exopolysaccharide is about 38.5% vol/vol.
69 . The method of claim 64 , wherein the red microalgae cells ore of the genus Porphyridium.
70 . (canceled)